# AMR Action Fund

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/amr-action-fund
Canonical HTML page: https://getbiobrief.com/entity/amr-action-fund

## Timeline

- **2026-03-10**: STAT Analysis Released — Data confirms a 35% nosedive in Big Pharma antimicrobial R&D over the preceding 60 months.
- **2025-11-20**: Small Biotech Crisis — A wave of bankruptcies among small antibiotic developers highlights the 'broken market' for new treatments.
- **2023-06-15**: Market Exit Acceleration — Several large pharma entities announce the closure of infectious disease units to focus on chronic therapies.
- **2021-03-10**: Baseline Period — Major drugmakers maintain active antimicrobial pipelines before a steady five-year decline begins.

## Recent coverage (1 stories)

### Big Pharma’s Antibiotic Pipeline Shrinks 35% as Market Failures Deepen
2026-03-10 11:45:16 · Sentiment: Negative · Impact: 7/10 · Sources: 2

A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics.
Full story: https://getbiobrief.com/story/big-pharma-antibiotic-pipeline-decline-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.